Recent Publications
207Reply to: 'The use of β-blockers after myocardial infarction: no doubts remain'.
Cleland JGF
Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes.
Fernández-Ruiz I
The use of β-blockers after myocardial infarction: no doubts remain.
Atar D, Munkhaugen J, Prescott EIB, Jernberg T, Ibáñez B
Cognitive Impairment in People With Diabetes-Related Foot Ulcers: A Multicentre, Case-Control, Observational Study.
Karunathilaka N, Lazzarini PA, MacAndrew M, Finlayson K, Parker C
Cognitive impairment is associated with people with diabetes-related foot ulcers (DFU). However, it is unclear if cognitive impairment is associated with the ulcer itself or other co-existing diabetes...
Safety of Physical Activity After Cervical Artery Dissection.
Mayer-Suess L, Kaufmann J, Traenka C, Felicetti S, Kaufmann S, Dejakum B, Enz LS, Ratzinger G, Truessel S, Gizewski ER, Kiechl S, Engelter S, Knoflach M
BACKGROUND: Cervical artery dissection (CeAD) is a major cause for stroke in young adults. A timely association with minor-to-moderate unimposing cervical trauma, which is often sports-related, is...
Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making?
Yogendrakumar V, Lun R, Campbell BCV, Ganesh A
Variations in thrombus composition significantly influence the efficacy of conventional thrombolytic therapies in acute ischemic stroke. Emerging treatments, designed to target distinct components of ...
Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
Nauck MA, Tuttle KR, Tschöp MH, Blüher M
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of...
Clopidogrel versus aspirin for coronary artery disease.
Dello Russo C, Venetucci L, Ramlogan R, Gagliardi D, Akintola A, Pirmohamed M
Clopidogrel versus aspirin for coronary artery disease - Authors' reply.
Valgimigli M, Gragnano F, Giacoppo D
Heart failure in the elderly: epidemiology, mechanisms, and management.
de Boer RA, Abdellatif M, Bauersachs J, Roger VL
There is no consensus on an age cut-off for being considered elderly, but the majority of patients with heart failure (HF) have an advanced age. The lifetime risk for developing HF is ∼25%, with a sha...
Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.
Lee SR, Go YH, Choi EK, Rha HW, Jeong MH, Choi J, Lee KY, Ahn HJ, Kwon S, Kim B, Jang MJ, Han KD, Oh S, Lip GYH
BACKGROUND AND AIMS: A recent European trial found that in frail elderly patients with atrial fibrillation (AF), switching from well-managed warfarin to direct oral anticoagulants (DOACs) was asso...
Understanding atrial failure: from diagnosis to clinical implications.
Alexander B, Braunwald E, Bayés-de-Luna A, Almufleh A, Bayés-Genís A, Baranchuk A
Atrial failure is an emerging clinical syndrome that results from an underlying atrial cardiomyopathy and is characterized by impaired atrial haemodynamic and/or electrical function that is sufficient...
Prenatal 'isolated' ventricular septal defect as a sentinel for latent monogenic cardiac disorders.
Liu J, Wang C, Shao S
Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.
Prange KHM, Bel-Bordes G, Depuydt MAC, Barlampas P, Reif MJ, Grönloh MLB, Kempkes RWM, Griffith GR, van Roomen C, Zhu Y, Edsfeldt A, Sun J, de Jong MJM, Mol BM, Slütter B, Bot I, Neele AE, de Kleijn DPV, de Borst GJ, Kroon J, Wezel A, Smeets HJ, Stroes ESG, van Buul JD, Goossens P, Kuiper J, Goncalves I, Pasterkamp G, Mokry M, de Winther MPJ
BACKGROUND AND AIMS: Atherosclerosis is a chronic lipid-driven inflammatory disease and one of the leading underlying causes of cardiovascular morbidity and mortality in Western society. Macrophag...
Igniting the future of cardiovascular care: highlights from the ESC Digital and AI Summit 2025 in Berlin.
Engelhardt S, Bruining N, Asselbergs FW
Barriers preventing consideration of environmental risk factors by cardiologists.
Montone RA, Münzel T, Luscher TF